What is the projected size of the genomics market by 2030?

Industry sources suggest the global genomics market could reach $90–120 billion by 2030, with mid-teens annual growth from 2026 onward. This expansion is driven by clinical sequencing in oncology, rare disease, and reproductive health, plus population genomics programs. Estimates incorporate falling sequencing costs, improved accuracy, streamlined informatics, and policy tailwinds in the EU that support data sharing and cohort-scale research. Company guidance at January conferences reinforces demand visibility across instruments and consumables.

Which companies are signaling demand momentum for 2026–2030?

Presentations and materials from Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, and PacBio indicate stronger throughput, workflow automation, and clinical integrations. These signals translate into higher instrument placements and sustained consumables usage, complemented by software subscriptions. Together, they support analyst projections of double-digit annual growth, with recurring revenue models built on reagents and informatics used in hospital labs and national genomics initiatives.

How do policy developments in Europe influence genomics adoption?

Late-2025 movement on European health data frameworks is expected to streamline cross-border data exchange and strengthen evidence generation for clinical genomics. This can accelerate guideline updates and reimbursement decisions, especially in oncology and rare disease applications. Analysts view these policies as adding incremental spending and improving scalability for national programs between 2026 and 2030, supporting the higher end of market projections if adoption proceeds as expected.

What are the key risks that could temper genomics growth through 2030?

Key risks include reimbursement variability, budget constraints impacting instrument procurement cycles, and regulatory timelines for clinical test approvals and data governance. Integration challenges across hospital IT, interoperability requirements, and quality management can also slow adoption. Analysts incorporate these factors into downside scenarios, while upside cases rely on faster clinical guideline changes, broader payer coverage, and continued declines in sequencing and informatics costs.

Which segments are expected to drive recurring revenue in genomics?

Recurring revenue is anticipated from consumables and informatics subscriptions that underpin clinical workflows. Oncological and rare disease sequencing generate frequent reagent use, while integrated software for analysis, interpretation, and reporting supports subscription models. Population genomics and translational research contribute steady demand, as cohorts require ongoing sequencing, data curation, and analytical updates over multi-year timelines, strengthening long-term revenue visibility.

Bloomberg Intelligence Sees Genomics Reaching $90-120 Billion by 2030

New projections from analysts and company guidance this week point to a robust expansion in genomics through 2030. Capacity additions at Illumina, Oxford Nanopore, PacBio, and Thermo Fisher, combined with policy tailwinds in the EU, underpin an estimated double-digit growth trajectory.

Published: January 9, 2026 By Sarah Chen Category: Genomics

Bloomberg Intelligence Sees Genomics Reaching $90-120 Billion by 2030

Executive Summary

Global genomics is projected to reach $90-120 billion by 2030, with an estimated 12-18% CAGR from 2026-2030, according to analyst notes and company guidance released in late 2025 and early 2026 (Bloomberg Intelligence; McKinsey Life Sciences).
Capacity expansions and portfolio updates from Illumina, Oxford Nanopore Technologies, PacBio, and Thermo Fisher Scientific at the January 2026 J.P. For more on [related climate tech developments](/microsoft-amazon-and-sap-upend-climate-tech-rivalries-with-carbon-deals-and-csrd-tools-03-01-2026). Morgan Healthcare Conference signal stronger instrument and consumables demand into 2027-2030 (J.P. Morgan Healthcare Conference).
EU health data policy developments in late 2025 are expected to accelerate adoption of clinical and population genomics across member states, supporting multi-year volume growth (European Commission press corner).
Clinical sequencing, oncology diagnostics, and population genomics programs are set to be primary revenue drivers, with consumables and informatics subscriptions contributing recurring cash flows (Reuters company coverage).

2026–2030 Outlook and Demand Drivers Analyst assessments published since late November suggest the genomics market is tracking toward $90-120 billion by 2030, with mid-teens annual growth anchored by falling sequencing costs and a broadening clinical footprint (Bloomberg Intelligence). The range reflects scenario-based uptake across clinical oncology, rare disease diagnostics, reproductive health, and population genomics cohorts, while factoring in reimbursement variability and regulatory timelines (McKinsey Life Sciences).

Recent company commentary and product pipeline updates point to higher throughput and workflow automation—from library prep to variant interpretation—reducing turnaround times and enabling new indications. At the J.P. Morgan Healthcare Conference this week, genomics vendors emphasized scaling capacity and informatics integrations that support hospital labs and national programs, reinforcing multi-year demand visibility (J.P. Morgan Healthcare Conference agenda...

Read the full article at AI BUSINESS 2.0 NEWS